ZymoGenetics, Novo Nordisk deal

NVO spun off its ZymoGenetics subsidiary and entered into an agreement under which NVO has an option to obtain certain marketing rights to product candidates resulting from ZymoGenetics' R&D. For diabetes product candidates, NVO would have worldwide rights and for other therapeutic categories, NVO's options cover all markets outside North America. NVO will own 51 percent of ZymoGenetics following the spinoff. ...